Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)
- 10 April 2002
- journal article
- case report
- Published by Wiley in Movement Disorders
- Vol. 17 (5) , 1098-1100
- https://doi.org/10.1002/mds.10209
Abstract
We report on a patient with cranio–cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A. © 2002 Movement Disorder SocietyKeywords
This publication has 8 references indexed in Scilit:
- Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparationsEuropean Journal of Neurology, 1999
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystoniaNeurology, 1999
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystoniaNeurology, 1999
- Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical responseNeurology, 1998
- Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonismMovement Disorders, 1998
- Response and immunoresistance to botulinum toxin injectionsNeurology, 1995
- Development of resistance to botulinum toxin type A in patients with torticollisMovement Disorders, 1994
- DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLISThe Lancet, 1986